Upper Limb Motor Function Affects the Outcome after Treatment with Botulinum Toxin A.


Journal

European neurology
ISSN: 1421-9913
Titre abrégé: Eur Neurol
Pays: Switzerland
ID NLM: 0150760

Informations de publication

Date de publication:
2019
Historique:
received: 28 12 2018
accepted: 25 03 2019
pubmed: 24 4 2019
medline: 27 6 2020
entrez: 24 4 2019
Statut: ppublish

Résumé

Treatment with Botulinum toxin A (BoNT-A) is effective in decreasing upper limb spasticity. This study aimed to determine the differences in the outcome based on the upper limb motor function before BoNT-A treatment. The subjects were 61 patients who underwent BoNT-A treatment for upper limb spasticity. Limb function was evaluated using the Fugl-Meyer Assessment upper extremity (FMA-UE), modified Ashworth scale, passive range of motion and disability assessment scale before treatment as well as 2, 6, and 12 weeks after treatment. We divided the total and each subscale of FMA-UE before BoNT-A administration into beyond-the-mean-score group (higher score group) and below-the-mean-score group (lower score group). In both the higher and lower score groups of the FMA-UE total and modified Ashworth scale scores improved significantly after treatment. In FMA-UE, the higher score group of subscale A improved significantly, but subscale C decreased significantly at 2 and 6 weeks after the administration. The lower score group of total, subscale A, and B improved significantly. In the disability assessment scale, the self-dressing capability at 6 weeks and limb position at 2, 6 and 12 weeks after the administration improved significantly in the higher score group. In the lower score group, the hygiene capability at 2 weeks as well as the dressing capability and limb position improved significantly at 2, 6 and 12 weeks after administration. The time course after administration of BoNT-A differed based on upper limb motor function before injection. When administering BoNT-A into the finger flexor muscles of a patient, we should carefully judge the indications for administration.

Sections du résumé

BACKGROUND
Treatment with Botulinum toxin A (BoNT-A) is effective in decreasing upper limb spasticity.
OBJECTIVE
This study aimed to determine the differences in the outcome based on the upper limb motor function before BoNT-A treatment.
METHODS
The subjects were 61 patients who underwent BoNT-A treatment for upper limb spasticity. Limb function was evaluated using the Fugl-Meyer Assessment upper extremity (FMA-UE), modified Ashworth scale, passive range of motion and disability assessment scale before treatment as well as 2, 6, and 12 weeks after treatment. We divided the total and each subscale of FMA-UE before BoNT-A administration into beyond-the-mean-score group (higher score group) and below-the-mean-score group (lower score group).
RESULTS
In both the higher and lower score groups of the FMA-UE total and modified Ashworth scale scores improved significantly after treatment. In FMA-UE, the higher score group of subscale A improved significantly, but subscale C decreased significantly at 2 and 6 weeks after the administration. The lower score group of total, subscale A, and B improved significantly. In the disability assessment scale, the self-dressing capability at 6 weeks and limb position at 2, 6 and 12 weeks after the administration improved significantly in the higher score group. In the lower score group, the hygiene capability at 2 weeks as well as the dressing capability and limb position improved significantly at 2, 6 and 12 weeks after administration.
CONCLUSIONS
The time course after administration of BoNT-A differed based on upper limb motor function before injection. When administering BoNT-A into the finger flexor muscles of a patient, we should carefully judge the indications for administration.

Identifiants

pubmed: 31013501
pii: 000499907
doi: 10.1159/000499907
doi:

Substances chimiques

Neuromuscular Agents 0
Botulinum Toxins, Type A EC 3.4.24.69

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

30-36

Informations de copyright

© 2019 S. Karger AG, Basel.

Auteurs

Kenta Fujimura (K)

Faculty of Rehabilitation, School of Health Sciences, Fujita Health University, Toyoake, Japan, fujimura@fujita-hu.ac.jp.

Hitoshi Kagaya (H)

Department of Rehabilitation Medicine I, School of Medicine, Fujita Health University, Toyoake, Japan.

Hisae Onaka (H)

Department of Rehabilitation, Fujita Health University Hospital, Toyoake, Japan.

Nao Nagasawa (N)

Department of Rehabilitation, Fujita Health University Hospital, Toyoake, Japan.

Akihito Ishihara (A)

Department of Rehabilitation, Fujita Health University Hospital, Toyoake, Japan.

Yuki Okochi (Y)

Department of Rehabilitation, Fujita Health University Hospital, Toyoake, Japan.

Masayuki Yamada (M)

Faculty of Rehabilitation, School of Health Sciences, Fujita Health University, Toyoake, Japan.

Hiroki Tanikawa (H)

Faculty of Rehabilitation, School of Health Sciences, Fujita Health University, Toyoake, Japan.

Yoshikiyo Kanada (Y)

Faculty of Rehabilitation, School of Health Sciences, Fujita Health University, Toyoake, Japan.

Eiichi Saitoh (E)

Department of Rehabilitation Medicine I, School of Medicine, Fujita Health University, Toyoake, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH